EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma

Lydia Giannitrapani iD, Francesca Di Gaudio iD, Melchiorre Cervello iD, Francesca Scionti iD, Domenico Ciliberto iD, Nicoletta Staropoli, Giuseppe Agapito iD, Mario Cannataro iD, Pierfrancesco Tassone iD, Pierosandro Tagliaferri, Aurelio Seidita iD, Maurizio Soresi iD und 9 weitere

International Journal of Molecular Sciences · 12.02.2024 · 25 (4) · 2197

DOI: 10.3390/ijms25042197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.02.2024. Verfasst von Lydia Giannitrapani und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antineoplastic Agents, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PSN2014 - Assessorato della Salute - Regione Siciliana prot./Area int.2/n.85890, PSN2014–Assessorato della Salute–Regione Siciliana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patient stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolism, and excretion (ADME)-related genes were evaluated to identify new potential predictive biomarkers of sorafenib response in HCC patients. Five known SNPs in angiogenesis-related genes, including VEGF-A, VEGF-C, HIF-1a, ANGPT2, and NOS3, were investigated in 34 HCC patients (9 sorafenib responders and 25 non-responders). A subgroup of 23 patients was genotyped for SNPs in ADME genes. A machine learning classifier method was used to discover classification rules for our dataset. We found that only the VEGF-A (rs2010963) C allele and CC genotype were significantly associated with sorafenib response. ADME-related gene analysis identified 10 polymorphic variants in ADH1A (rs6811453), ADH6 (rs10008281), SULT1A2/CCDC101 (rs11401), CYP26A1 (rs7905939), DPYD (rs2297595 and rs1801265), FMO2 (rs2020863), and SLC22A14 (rs149738, rs171248, and rs183574) significantly associated with sorafenib response. We have identified a genetic signature of predictive response that could permit non-responder/responder patient stratification. Angiogenesis- and ADME-related genes correlation was confirmed by cumulative genetic risk score and network and pathway enrichment analysis. Our findings provide a proof of concept that needs further validation in follow-up studies for HCC patient stratification for sorafenib prescription.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAntineoplastic AgentsLiver NeoplasmsHumansSorafenibVascular Endothelial Growth Factor ANiacinamidePhenylurea CompoundsGenetic Markers

Stichwörter der Autor:innen

anticancer drugsgenetic polymorphismgenotypingpharmacogenomics

Substanzen

SorafenibAntineoplastic AgentsVascular Endothelial Growth Factor ANiacinamidePhenylurea CompoundsGenetic Markers

Autor:innen und Institutionen

  • Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.
  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
  • Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.
  • Medical and Translational Oncology Unit, A.O.U. R. Dulbecco, 88100 Catanzaro, Italy.
  • Department of Legal, Economic and Social Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
  • Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.

ORCID-Profile: Lydia Giannitrapani, Francesca Di Gaudio, Melchiorre Cervello, Francesca Scionti, Domenico Ciliberto, Giuseppe Agapito, Mario Cannataro, Pierfrancesco Tassone, Aurelio Seidita, Maurizio Soresi, Gaetano Bertino, Rosaria Ciriminna, Mariamena Arbitrio

Förderung

  • PSN2014 - Assessorato della Salute - Regione Siciliana prot./Area int.2/n.85890
  • PSN2014–Assessorato della Salute–Regione Siciliana

Zitieren

APA

Giannitrapani, L., Di Gaudio, F., Cervello, M., Scionti, F., Ciliberto, D., Staropoli, N., Agapito, G., Cannataro, M., Tassone, P., Tagliaferri, P., Seidita, A., Soresi, M., Affronti, M., Bertino, G., Russello, M., Ciriminna, R., Lino, C., Spinnato, F., Verderame, F., …, & Arbitrio, M. (2024). Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 25(4), 2197. https://doi.org/10.3390/ijms25042197

Vancouver

Giannitrapani L, Di Gaudio F, Cervello M, Scionti F, Ciliberto D, Staropoli N, et al. Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2024;25(4):2197. doi:10.3390/ijms25042197

BibTeX
@article{Giannitrapani2024,
  author = {Giannitrapani, Lydia and Di Gaudio, Francesca and Cervello, Melchiorre and Scionti, Francesca and Ciliberto, Domenico and Staropoli, Nicoletta and Agapito, Giuseppe and Cannataro, Mario and Tassone, Pierfrancesco and Tagliaferri, Pierosandro and Seidita, Aurelio and Soresi, Maurizio and Affronti, Marco and Bertino, Gaetano and Russello, Maurizio and Ciriminna, Rosaria and Lino, Claudia and Spinnato, Francesca and Verderame, Francesco and Augello, Giuseppa and Arbitrio, Mariamena},
  title = {Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {4},
  pages = {2197},
  doi = {10.3390/ijms25042197}
}
Kostenlos starten →